{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:47:01Z","timestamp":1788446821653,"version":"build-2803163510"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T00:00:00Z","timestamp":1740960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Nasopharyngeal carcinoma (NPC) is a rare epithelial malignancy arising from the mucosal lining of the nasopharynx, with significant geographic prevalence in East and Southeast Asia. Despite advances in diagnostic imaging and treatment modalities, over 70% of NPC cases are diagnosed at advanced stages (III\/IV), leading to a high risk of recurrence and metastasis. Conventional salvage treatments for recurrent\/metastatic NPC, including radiotherapy and chemotherapy, often demonstrate limited efficacy and poor overall survival outcomes. Recently, immunotherapy has emerged as a promising therapeutic approach, modulating the tumor microenvironment and enhancing the immune system\u2019s ability to target cancer cells. This case report describes an unresectable recurrent NPC treated with immunotherapy, underscoring the potential of immune-based therapies in managing advanced NPC.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case presentation<\/jats:title><jats:p>A 51-year-old male, with a medical history of hypercholesterolemia and a right parietal ganglioglioma, presented with undifferentiated, infiltrating non-keratinizing NPC diagnosed in 2022. Initial MRI and PET\/CT scans revealed locally advanced disease, prompting induction chemotherapy followed by chemoradiotherapy. Although the patient experienced several chemotherapy-related complications, follow-up imaging indicated significant tumor reduction. He subsequently underwent concurrent chemoradiotherapy, achieving stable disease. In late 2023, recurrence was identified, and biopsy confirmed EBV-positive NPC. A multidisciplinary team evaluated the case, considering options for re-irradiation and surgical intervention. However, due to the tumor\u2019s location and associated surgical risks, the decision was made to initiate first-line systemic therapy with platinum salts and gemcitabine, followed by immunotherapy with Pembrolizumab. Post-chemotherapy assessments revealed undetectable EBV DNA levels and a complete radiological response. Instrumental reassessment confirmed a complete response, with a negative EBV DNA plasma evaluation. The continued success of systemic therapy and close monitoring remained the focus of the patient\u2019s care.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>This case underscores the complexity of managing recurrent NPC and the importance of a multidisciplinary approach. It highlights the evolving role of immunotherapy in treatment strategies, demonstrating its potential to improve outcomes in recurrent\/metastatic NPC. Ongoing research is essential to further advance treatment options for this challenging condition. The patient remains under close follow-up, with surgery considered a potential option, given the sustained radiological response.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2025.1523481","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:04:48Z","timestamp":1740985488000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Case Report: Unresectable recurrent nasopharyngeal cancer treated with immuno oncology"],"prefix":"10.3389","volume":"15","author":[{"given":"Fabiano","family":"Flauto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maria","family":"Di Crescenzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Damiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.canlet.2016.01.040","article-title":"Global trends in incidence and mortality of nasopharyngeal carcinoma","volume":"374","author":"Tang","year":"2016","journal-title":"Cancer Lett"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.7150\/thno.82690","article-title":"Nasopharyngeal carcinoma ecology theory: cancer as multidimensional spatiotemporal \u201cunity of ecology and evolution\u201d pathological ecosystem","volume":"13","author":"Luo","year":"2023","journal-title":"Theranostics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s40880-016-0103-5","article-title":"A new prognostic histopathologic classification of nasopharyngeal carcinoma","volume":"35","author":"Wang","year":"2016","journal-title":"Chin J Cancer"},{"key":"B5","article-title":"Undifferentiated, nonkeratinizing, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia","volume":"146","author":"Pathmanathan","year":"1995","journal-title":"Am J Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.0016","article-title":"NCCN guidelines\u00ae Insights: head and neck cancers, version 1.2022","volume":"20","author":"Caudell","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.5165","article-title":"Prognostic model for stratification of radioresistant nasopharynx carcinoma to curative salvage radiotherapy","volume":"36","author":"Li","year":"2018","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"96","DOI":"10.4143\/crt.2020.1349","article-title":"Re-irradiation with moderate hypo-fractionation using intensity modulated photon or proton radiation therapy in locally recurrent squamous cell carcinoma of nasopharynx","volume":"54","author":"Nam","year":"2022","journal-title":"Cancer Res Treat"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30673-2","article-title":"Endoscopic surgery compared with intensity-modulated radiotherapy in resectable locally recurrent nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial","volume":"22","author":"Liu","year":"2021","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.06.009","article-title":"A prospective multicentre phase II study of cisplatin and weekly docetaxel as first-line treatment for recurrent or metastatic nasopharyngeal cancer (KCSG HN07-01)","volume":"48","author":"Ji","year":"2012","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/cad.0b013e32832c9c51","article-title":"Docetaxel in the management of head and neck cancer","volume":"20","author":"Caponigro","year":"2009","journal-title":"Anticancer Drugs"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00396","article-title":"Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as first-line therapy for recurrent or metastatic nasopharyngeal carcinoma: final overall survival analysis of GEM20110714 phase III study","volume":"39","author":"Hong","year":"2021","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0131-9","article-title":"Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012","volume":"119","author":"Mehra","year":"2018","journal-title":"Br J Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)31999-8","article-title":"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study","volume":"393","author":"Cohen","year":"2019","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: the JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02712","article-title":"Efficacy, safety, and correlative biomarkers of toripalimab in previously treated recurrent or metastatic nasopharyngeal carcinoma: A phase II clinical trial (POLARIS-02)","volume":"39","author":"Wang","year":"2021","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00302-8","article-title":"Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial","volume":"22","author":"Yang","year":"2021","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.04.014","article-title":"Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)","volume":"41","author":"Yang","year":"2023","journal-title":"Cancer Cell"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and antitumor activity of pembrolizumab in patients with programmed death-ligand 1-positive nasopharyngeal carcinoma: results of the KEYNOTE-028 study","volume":"35","author":"Hsu","year":"2017","journal-title":"J Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.007","article-title":"Pembrolizumab monotherapy versus chemotherapy in platinum-pretreated, recurrent or metastatic nasopharyngeal cancer (KEYNOTE-122): an open-label, randomized, phase III trial","volume":"34","author":"Chan","year":"2023","journal-title":"Ann Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00739","article-title":"Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I\/II checkMate 358 trial","volume":"37","author":"Naumann","year":"2019","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor activity of nivolumab in recurrent and metastatic nasopharyngeal carcinoma: an international, multicenter study of the mayo clinic phase 2 consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1523481\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:04:50Z","timestamp":1740985490000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1523481\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,3]]},"references-count":24,"alternative-id":["10.3389\/fonc.2025.1523481"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1523481","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,3]]},"article-number":"1523481"}}